MSDL vs RARE · P/E 15, $1.29B cap vs rev $350.0M
Morgan Stanley Direct Lending Fund (MSDL) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Morgan Stanley Direct Lending Fund (MSDL) is a asset management company listed on NYSE.
Ultragenyx (RARE) is a biotechnology company listed on US.
MSDL does not have a complete income-statement cache yet.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
MSDL currently screens at market cap $1.29B and trailing P/E 15.0. RARE currently screens at market cap $2.79B.
Not investment advice. Open the MSDL and RARE stock pages for the full models.
Not investment advice.